First human test for novel HIV vaccine completed
NCT ID NCT03934541
Summary
This was a small, early-stage study to check the safety and immune response of a new HIV vaccine in healthy adults. It involved 24 participants who received either the vaccine or a placebo. The main goal was to see if the vaccine was safe and if it triggered an immune response, not to test if it prevents HIV infection.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alabama CRS
Birmingham, Alabama, 35294, United States
-
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
Boston, Massachusetts, 02115-6110, United States
-
Columbia P&S CRS
New York, New York, 10032-3732, United States
-
Fenway Health (FH) CRS
Boston, Massachusetts, 02215-4302, United States
-
New York Blood Center CRS
New York, New York, 10065, United States
-
Seattle Vaccine and Prevention CRS
Seattle, Washington, 98109-1024, United States
Conditions
Explore the condition pages connected to this study.